1218 related articles for article (PubMed ID: 28743155)
1. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
[TBL] [Abstract][Full Text] [Related]
2. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
[TBL] [Abstract][Full Text] [Related]
3. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
[TBL] [Abstract][Full Text] [Related]
4. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.
Meeks JJ; Taylor JM; Matsushita K; Herr HW; Donat SM; Bochner BH; Dalbagni G
BJU Int; 2013 Jun; 111(8):E325-30. PubMed ID: 23384236
[TBL] [Abstract][Full Text] [Related]
5. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
6. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M;
Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925
[TBL] [Abstract][Full Text] [Related]
7. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
8. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
[TBL] [Abstract][Full Text] [Related]
9. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
[TBL] [Abstract][Full Text] [Related]
10. Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy.
Moschini M; Soria F; Klatte T; Wirth GJ; Özsoy M; Gust K; Briganti A; Roupret M; Susani M; Haitel A; Shariat SF
Clin Genitourin Cancer; 2017 Apr; 15(2):e267-e273. PubMed ID: 27530435
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy for bladder cancer.
Sonpavde G; Lerner SP
Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy preceding cystectomy for bladder cancer.
Sonpavde G; Amiel GE; Mims MP; Hayes TG; Lerner SP
Expert Opin Pharmacother; 2008 Aug; 9(11):1885-93. PubMed ID: 18627327
[TBL] [Abstract][Full Text] [Related]
14. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
Weight CJ; Garcia JA; Hansel DE; Fergany AF; Campbell SC; Gong MC; Jones JS; Klein EA; Dreicer R; Stephenson AJ
Cancer; 2009 Feb; 115(4):792-9. PubMed ID: 19127557
[TBL] [Abstract][Full Text] [Related]
15. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.
Turker P; Bostrom PJ; Wroclawski ML; van Rhijn B; Kortekangas H; Kuk C; Mirtti T; Fleshner NE; Jewett MA; Finelli A; Kwast TV; Evans A; Sweet J; Laato M; Zlotta AR
BJU Int; 2012 Sep; 110(6):804-11. PubMed ID: 22321341
[TBL] [Abstract][Full Text] [Related]
16. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
Raj GV; Karavadia S; Schlomer B; Arriaga Y; Lotan Y; Sagalowsky A; Frenkel E
Cancer; 2011 Jan; 117(2):276-82. PubMed ID: 20830767
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ
Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593
[TBL] [Abstract][Full Text] [Related]
18. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
Culp SH; Dickstein RJ; Grossman HB; Pretzsch SM; Porten S; Daneshmand S; Cai J; Groshen S; Siefker-Radtke A; Millikan RE; Czerniak B; Navai N; Wszolek MF; Kamat AM; Dinney CP
J Urol; 2014 Jan; 191(1):40-7. PubMed ID: 23911605
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
20. Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy.
Dursun F; Elshabrawy A; Wang H; Wu S; Liss MA; Kaushik D; Grosser D; Svatek RS; Mansour AM
Urol Oncol; 2022 Jun; 40(6):275.e1-275.e10. PubMed ID: 35351370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]